Baxter International has entered into a definitive agreement to sell its Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial terms were not disclosed.   The Vero cell platform is an advanced, cell-based technology for vaccine production, including vaccines for H5N1, H1N1 and seasonal flu. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus....